Nathalie El Omeiri

Nathalie El Omeiri

Auto-generated profile, based on publicly available information

Nathalie El Omeiri

Antimicrobial Resitance Unit, Pan American Health Organization, Washington, DC, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Vaccine
Verified
Journal Article
Open access
CSChristoph A Steffen
Christoph A Steffen
LHLouise Henaff
Louise Henaff
ADAntoine Durupt
Antoine Durupt
NONathalie El Omeiri
Nathalie El Omeiri
SNSidy Ndiaye
Sidy Ndiaye
JHJoachim Hombach
Joachim Hombach
Countries face an increasingly complex vaccination landscape. As well as ever-changing infectious disease epidemiology, the number and diversity of vaccine-preventable diseases, vaccine products, and vaccine technologies continue to increase. To ensure that vaccination decision-making is transparent, country-owned and informed by sound scientific evidence, many countries have established national immunization technical advisory groups (NITAGs) to provide independent expert advice. The past decade has seen substantial growth in NITAG numbers and functionality, and there is now a need to consolidate this progress, by further capacity building, to ensure that NITAGs are responsive to the changing face of immunization over the next decade.

26 February 2022 in American Journal of Infection Control
Verified
Journal Article
Open access
FVFrancisca Verdugo-Paiva
Francisca Verdugo-Paiva
FOFernando Otaiza
Fernando Otaiza
PRPablo Roson-Rodríguez
Pablo Roson-Rodríguez
AGAna María Rojas Gómez
Ana María Rojas Gómez
MGMarcelo Galas
Marcelo Galas
PRPilar Ramón-Pardo
Pilar Ramón-Pardo
This systematic review aims to summarize the evidence on the effects of screening strategies to detect carbapenem-resistant gram-negative bacteria (Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa). Eligible studies were randomized trials, non-randomized controlled trials, controlled before-after studies, and interrupted time series. We conducted searches in CENTRAL, PUBMED, Embase, Epistemonikos, and in multiple databases available in the Virtual Health Library (LILACS, Scielo, WHO IBECS, and PAHO IBECS). All the searches covered the period until 4 June 2021. No date or language restrictions were applied. Two reviewers independently evaluated potentially eligible studies according to predefined selection criteria, and extracted data on study characteristics, methods, outcomes, and risk of bias, using a predesigned standardized form. When possible, we intended to conduct meta-analyses using a random-effect model. We assessed the certainty of the evidence (CoE) and summarized the results using the GRADE approach. Our search strategy yielded 57,451 references. No randomized trials were identified. Sixteen studies (one controlled before-after study and 15 interrupted time series) met our inclusion criteria and were included in the review. Most studies were conducted in tertiary care general hospitals from the United States, Europe, and Asia. Eleven studies included adult patients hospitalized in general wards and intensive care units, one was carried out in a neonatal intensive care unit, two in hematology or oncology units, and one in a solid organ transplantation department. Eleven studies were conducted in the setting of an outbreak. Regarding the detection strategy used, all studies included screening strategies for high-risk patients at the moment of admission and 7 studies reported a contact surveillance strategy. Most studies were conducted in settings where infection prevention and control measures were concomitantly installed or reinforced. Data were not suitable for meta-analysis, so the results were presented as a narrative synthesis. Most studies showed a decline in the prevalence of both infection and colonization rates after the implementation of a policy of active surveillance, but the CoE is low. Screening strategies may result in little to no difference in the risk of all-cause mortality and the length of hospital stay. Existing evidence may favor the use of surveillance culture to carbapenem-resistant gram-negative bacteria, but its quality is poor, so solid conclusions cannot be drawn. Well-conducted randomized trials or high-quality quasi-experimental studies are needed to improve the certainty of the existing evidence. These studies should assess the effect of the addition of screening strategies as a single intervention and measure clinically important outcomes such as infection, length of hospital stay, and mortality.

25 September 2022 in Expert Review of Vaccines
Verified
Journal Article
Open access
LOLucia H. De Oliveira
Lucia H. De Oliveira
CJCara B. Janusz
Cara B. Janusz
MCMaria Tereza Da Costa
Maria Tereza Da Costa
NONathalie El Omeiri
Nathalie El Omeiri
PBPaul Bloem
Paul Bloem
SLSilvana Luciani
Silvana Luciani
Human papillomavirus (HPV) is an important public health concern due to its causative role in many cancers, especially cervical cancer, and other conditions that lead to serious health consequences...

1 August 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
AFAnai García Fariñas
Anai García Fariñas
NLNivaldo Linares-Pérez
Nivaldo Linares-Pérez
ACAndrew Clark
Andrew Clark
MTMaría Eugenia Toledo-Romaní
María Eugenia Toledo-Romaní
NONathalie El Omeiri
Nathalie El Omeiri
APAlina Pérez
Alina Pérez
To evaluate the cost-effectiveness of introducing a domestic pneumococcal conjugate vaccine (PCV7-TT) into the Cuban National Immunization Program (NIP). We compared PCV7-TT given at two, four and six months of age to a scenario without PCV7-TT, over a ten-year period (2020-2029). We calculated the cost (Cuban pesos - CUP) per Disability Adjusted Life Year (DALY) averted from a Government perspective. We compared results from a static cohort model and a parsimonious prediction model informed by the serotype distribution among pneumococcal carriers and cases. We ran probabilistic and deterministic uncertainty analyses. PCV7-TT could prevent 6,897 (95% uncertainty interval, 4,344 - 8,750) hospitalizations and 189 (115 - 253) deaths in children <5 years of age, over the period 2020-2029. This could cost around 25 million (20-31) discounted CUP but would be offset by treatment cost savings of around 23 million (14-31). A parsimonious model predicted less favourable impact and cost-effectiveness but the cost per DALY averted was still less than 0.4 times the current GDP per capita. PCV7-TT is likely to be cost-effective in Cuba. The impact of the vaccine would need to be carefully monitored following its introduction into the NIP.

14 May 2021 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Closed access
IJImane Jroundi
Imane Jroundi
MBMohammed Benazzouz
Mohammed Benazzouz
AYAbdel Hakim Yahyane
Abdel Hakim Yahyane
MAMoulay Tahar Alaoui
Moulay Tahar Alaoui
NONathalie El Omeiri
Nathalie El Omeiri
The main mission of a National Immunization Technical Advisory Group (NITAG) is to provide impartial, evidence-based recommendations on immunization to the Ministry of Health. We report on the findings from an evaluation of the Moroccan NITAG with emphasis on its functionality, quality of work processes and outputs, and its integration into the immunization policy process. We conducted a cross-sectional study from October to December 2019. We used the standardized, US-CDC/WHO-developed “simplified assessment tool for national immunization technical advisory groups”. The evaluation included eight participants. The evaluation has shown that it fully complies with the WHO recommendations. Among its strengths, the Moroccan NITAG has a solid legal basis, diverse expertise and many years of combined experience. This composition contributed to the credibility and strength of its recommendations and facilitated their implementation. The NITAG could, however, benefit from implementing written declarations of interests and standardized operating procedures in addition to establishing a standardized methodology to guide and document the decision-making process. The Moroccan NITAG could also gain from inviting members with public health/epidemiology research experience and from exchanging with other NITAGs in the region and globally. Finally, ensuring sustainable funding for the NITAG‘s activities will be crucial, so that it can continue its valuable support to the national immunization program.